Angiogenesis and hypertension

The dual role of anti-hypertensive and anti-angiogenic therapies

Patrizia Ferroni, David Della Morte, Raffaele Palmirotta, Tatjana Rundek, Fiorella Guadagni, Mario Roselli

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Essential hypertension may be a consequence of structural and functional alterations of the microvascular network growth resulting partly from abnormal regulation of vascular endothelial growth factor (VEGF), one of the most potent known angiogenic factors. As data from clinical trials on anti-VEGF drugs are becoming available, it is increasingly recognized that VEGF, in addition to being a proliferation and migration factor, is also a maintenance and protection factor for endothelial cells, whose altered regulation may cause a disturbance of vascular homeostasis. Elevated VEGF levels in hypertensive patients were shown to correlate with cardiovascular risk, early microvascular and target organ damage; accordingly treatment of hypertension significantly reduced VEGF levels. Recently and in agreement with the theory that impaired angiogenesis can contribute to increased peripheral resistance and raised blood pressure (BP), an involvement of VEGF gene promoter polymorphisms in the pathophysiology of hypertension has been hypothesized. In the last decade, anti-VEGF drugs have been used in clinical practice, especially in the oncology field. This review will summarize the present understanding of the contribution of VEGF to neoangiogenesis in hypertension and its possible role as a marker of vascular damage. Given the well established effects that antihypertensive drugs exert on the vasculature beyond BP lowering (pleiotropic effects), we will also discuss the effects of antihypertensive treatment on circulating VEGF levels. The biological mechanism and clinical impact of hypertensive complications during anti-angiogenic treatments will also be reviewed.

Original languageEnglish
Pages (from-to)479-493
Number of pages15
JournalCurrent Vascular Pharmacology
Volume10
Issue number4
DOIs
StatePublished - Jul 1 2012

Fingerprint

Antihypertensive Agents
Vascular Endothelial Growth Factor A
Hypertension
Therapeutics
Blood Vessels
Blood Pressure
Angiogenesis Inducing Agents
Microvessels
Pharmaceutical Preparations
Vascular Resistance
Homeostasis
Endothelial Cells
Maintenance
Clinical Trials
Growth
Genes

Keywords

  • Angiogenesis
  • Antihypertensive drugs
  • Bevacizumab
  • Endothelium
  • Essential hypertension
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology

Cite this

Angiogenesis and hypertension : The dual role of anti-hypertensive and anti-angiogenic therapies. / Ferroni, Patrizia; Della Morte, David; Palmirotta, Raffaele; Rundek, Tatjana; Guadagni, Fiorella; Roselli, Mario.

In: Current Vascular Pharmacology, Vol. 10, No. 4, 01.07.2012, p. 479-493.

Research output: Contribution to journalArticle

Ferroni, Patrizia ; Della Morte, David ; Palmirotta, Raffaele ; Rundek, Tatjana ; Guadagni, Fiorella ; Roselli, Mario. / Angiogenesis and hypertension : The dual role of anti-hypertensive and anti-angiogenic therapies. In: Current Vascular Pharmacology. 2012 ; Vol. 10, No. 4. pp. 479-493.
@article{d4add2c0a3894742b4c9f4944b83230c,
title = "Angiogenesis and hypertension: The dual role of anti-hypertensive and anti-angiogenic therapies",
abstract = "Essential hypertension may be a consequence of structural and functional alterations of the microvascular network growth resulting partly from abnormal regulation of vascular endothelial growth factor (VEGF), one of the most potent known angiogenic factors. As data from clinical trials on anti-VEGF drugs are becoming available, it is increasingly recognized that VEGF, in addition to being a proliferation and migration factor, is also a maintenance and protection factor for endothelial cells, whose altered regulation may cause a disturbance of vascular homeostasis. Elevated VEGF levels in hypertensive patients were shown to correlate with cardiovascular risk, early microvascular and target organ damage; accordingly treatment of hypertension significantly reduced VEGF levels. Recently and in agreement with the theory that impaired angiogenesis can contribute to increased peripheral resistance and raised blood pressure (BP), an involvement of VEGF gene promoter polymorphisms in the pathophysiology of hypertension has been hypothesized. In the last decade, anti-VEGF drugs have been used in clinical practice, especially in the oncology field. This review will summarize the present understanding of the contribution of VEGF to neoangiogenesis in hypertension and its possible role as a marker of vascular damage. Given the well established effects that antihypertensive drugs exert on the vasculature beyond BP lowering (pleiotropic effects), we will also discuss the effects of antihypertensive treatment on circulating VEGF levels. The biological mechanism and clinical impact of hypertensive complications during anti-angiogenic treatments will also be reviewed.",
keywords = "Angiogenesis, Antihypertensive drugs, Bevacizumab, Endothelium, Essential hypertension, Vascular endothelial growth factor",
author = "Patrizia Ferroni and {Della Morte}, David and Raffaele Palmirotta and Tatjana Rundek and Fiorella Guadagni and Mario Roselli",
year = "2012",
month = "7",
day = "1",
doi = "10.2174/157016112800812836",
language = "English",
volume = "10",
pages = "479--493",
journal = "Current Vascular Pharmacology",
issn = "1570-1611",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - Angiogenesis and hypertension

T2 - The dual role of anti-hypertensive and anti-angiogenic therapies

AU - Ferroni, Patrizia

AU - Della Morte, David

AU - Palmirotta, Raffaele

AU - Rundek, Tatjana

AU - Guadagni, Fiorella

AU - Roselli, Mario

PY - 2012/7/1

Y1 - 2012/7/1

N2 - Essential hypertension may be a consequence of structural and functional alterations of the microvascular network growth resulting partly from abnormal regulation of vascular endothelial growth factor (VEGF), one of the most potent known angiogenic factors. As data from clinical trials on anti-VEGF drugs are becoming available, it is increasingly recognized that VEGF, in addition to being a proliferation and migration factor, is also a maintenance and protection factor for endothelial cells, whose altered regulation may cause a disturbance of vascular homeostasis. Elevated VEGF levels in hypertensive patients were shown to correlate with cardiovascular risk, early microvascular and target organ damage; accordingly treatment of hypertension significantly reduced VEGF levels. Recently and in agreement with the theory that impaired angiogenesis can contribute to increased peripheral resistance and raised blood pressure (BP), an involvement of VEGF gene promoter polymorphisms in the pathophysiology of hypertension has been hypothesized. In the last decade, anti-VEGF drugs have been used in clinical practice, especially in the oncology field. This review will summarize the present understanding of the contribution of VEGF to neoangiogenesis in hypertension and its possible role as a marker of vascular damage. Given the well established effects that antihypertensive drugs exert on the vasculature beyond BP lowering (pleiotropic effects), we will also discuss the effects of antihypertensive treatment on circulating VEGF levels. The biological mechanism and clinical impact of hypertensive complications during anti-angiogenic treatments will also be reviewed.

AB - Essential hypertension may be a consequence of structural and functional alterations of the microvascular network growth resulting partly from abnormal regulation of vascular endothelial growth factor (VEGF), one of the most potent known angiogenic factors. As data from clinical trials on anti-VEGF drugs are becoming available, it is increasingly recognized that VEGF, in addition to being a proliferation and migration factor, is also a maintenance and protection factor for endothelial cells, whose altered regulation may cause a disturbance of vascular homeostasis. Elevated VEGF levels in hypertensive patients were shown to correlate with cardiovascular risk, early microvascular and target organ damage; accordingly treatment of hypertension significantly reduced VEGF levels. Recently and in agreement with the theory that impaired angiogenesis can contribute to increased peripheral resistance and raised blood pressure (BP), an involvement of VEGF gene promoter polymorphisms in the pathophysiology of hypertension has been hypothesized. In the last decade, anti-VEGF drugs have been used in clinical practice, especially in the oncology field. This review will summarize the present understanding of the contribution of VEGF to neoangiogenesis in hypertension and its possible role as a marker of vascular damage. Given the well established effects that antihypertensive drugs exert on the vasculature beyond BP lowering (pleiotropic effects), we will also discuss the effects of antihypertensive treatment on circulating VEGF levels. The biological mechanism and clinical impact of hypertensive complications during anti-angiogenic treatments will also be reviewed.

KW - Angiogenesis

KW - Antihypertensive drugs

KW - Bevacizumab

KW - Endothelium

KW - Essential hypertension

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=84861662862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861662862&partnerID=8YFLogxK

U2 - 10.2174/157016112800812836

DO - 10.2174/157016112800812836

M3 - Article

VL - 10

SP - 479

EP - 493

JO - Current Vascular Pharmacology

JF - Current Vascular Pharmacology

SN - 1570-1611

IS - 4

ER -